Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2025
PHARMAC reconsiders oestradiol patch options following community feedback
29 January 2025 - PHARMAC is reviewing and reconsidering its oestradiol patch options after considerable feedback was received when it ...
Posted by Michael Wonder on 16 Jan 2025
PHARMAC consulting on widening access to venetoclax, azacitidine and upadacitinib monohydrate
16 January 2025 - PHARMAC is asking for feedback on a proposal to widen access to three medicines for five ...
Posted by Michael Wonder on 12 Jan 2025
2,000 people to benefit from medicine for osteoporosis and people with high blood calcium and cancer
10 January 2025 - PHARMAC is widening access to a medicine called denosumab for people with osteoporosis. ...
Posted by Michael Wonder on 03 Jan 2025
New Zealand Pharmaceutical Schedule - 1 January 2025
1 January 2025 - The January 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 24 Dec 2024
PHARMAC publishes agenda for February 2025 PTAC meeting
23 December 2024 - PHARMAC has published information on what the PTAC will be considering at its upcoming meeting in ...
Posted by Michael Wonder on 22 Dec 2024
PHARMAC consulting on six medicines for New Zealanders
19 December 2024 - PHARMAC is asking for feedback on proposals to fund six medicines for cancer and antibiotic resistant ...
Posted by Michael Wonder on 10 Dec 2024
PHARMAC seeks feedback to fund medicines for liver and ovarian cancer
9 December 2024 - PHARMAC is consulting on a proposal to fund bevacizumab (branded as Vegzelma) as a cancer medicine ...
Posted by Michael Wonder on 05 Dec 2024
PHARMAC funds more cancer and respiratory medicines for New Zealanders
6 December 2024 - More publicly funded medicines are on the way for people with types of breast and lung ...
Posted by Michael Wonder on 03 Dec 2024
New Zealand Pharmaceutical Schedule - 1 December 2024
1 December 2024 - The December 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 12 Nov 2024
New heart medicine for 18,000 New Zealanders
12 November 2024 - PHARMAC has decided to fund the medicine empagliflozin for thousands of people with a type of ...
Posted by Michael Wonder on 11 Nov 2024
PHARMAC funds new medicine and removes renewal criteria for ADHD and narcolepsy treatments
11 November 2024 - PHARMAC will make two changes for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy this ...
Posted by Michael Wonder on 08 Nov 2024
Newly funded medicine to benefit 110 more people with thyroid, liver, and kidney cancer
8 November 2024 - PHARMAC has decided to fund lenvatinib from 1 December 2024 for people with some types of ...
Posted by Michael Wonder on 07 Nov 2024
PHARMAC publishes agenda for the November 2024 PTAC meeting
6 November 2024 - PHARMAC has published the agenda for the upcoming 14-15 November 2024 PTAC meeting. ...
Posted by Michael Wonder on 01 Nov 2024
10,000 New Zealanders set to benefit from PHARMAC budget increase
1 November 2024 - Thirteen new medicines funded from today will benefit thousands of New Zealanders with various health conditions ...
Posted by Michael Wonder on 31 Oct 2024
PHARMAC looks to fund a medicine to keep bones strong
31 October 2024 - PHARMAC is consulting on a proposal to widen access to denosumab for more people with osteoporosis and ...